Published in Theranostics on January 10, 2012
Tobacco mosaic virus rods and spheres as supramolecular high-relaxivity MRI contrast agents. J Mater Chem B Mater Biol Med (2013) 1.10
Superparamagnetic nanoparticle clusters for cancer theranostics combining magnetic resonance imaging and hyperthermia treatment. Theranostics (2013) 1.07
Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents. Int J Nanomedicine (2015) 1.02
Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. Biomaterials (2012) 1.02
Magnetic nanoparticle-based theranostics. Theranostics (2012) 0.98
Engineering Gd-loaded nanoparticles to enhance MRI sensitivity via T(1) shortening. Nanotechnology (2013) 0.97
Casein-coated iron oxide nanoparticles for high MRI contrast enhancement and efficient cell targeting. ACS Appl Mater Interfaces (2013) 0.91
Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner. Int J Nanomedicine (2012) 0.90
MR imaging and targeting of a specific alveolar macrophage subpopulation in LPS-induced COPD animal model using antibody-conjugated magnetic nanoparticles. Int J Nanomedicine (2014) 0.86
Magnetic Nanoparticle Facilitated Drug Delivery for Cancer Therapy with Targeted and Image-Guided Approaches. Adv Funct Mater (2016) 0.84
Differentiation of reactive and tumor metastatic lymph nodes with diffusion-weighted and SPIO-enhanced MRI. Mol Imaging Biol (2013) 0.83
A symmetrical fluorous dendron-cyanine dye-conjugated bimodal nanoprobe for quantitative 19F MRI and NIR fluorescence bioimaging. Adv Healthc Mater (2014) 0.79
Virus-based nanomaterials as positron emission tomography and magnetic resonance contrast agents: from technology development to translational medicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.79
Liposomes Loaded with Hydrophobic Iron Oxide Nanoparticles: Suitable T₂ Contrast Agents for MRI. Int J Mol Sci (2016) 0.79
Ultrasmall cationic superparamagnetic iron oxide nanoparticles as nontoxic and efficient MRI contrast agent and magnetic-targeting tool. Int J Nanomedicine (2015) 0.77
Facile non-hydrothermal synthesis of oligosaccharides coated sub-5 nm magnetic iron oxide nanoparticles with dual MRI contrast enhancement effect. J Mater Chem B Mater Biol Med (2014) 0.77
Gadolinium embedded iron oxide nanoclusters as T1-T2 dual-modal MRI-visible vectors for safe and efficient siRNA delivery. Nanoscale (2013) 0.76
Preclinical evaluation of a urokinase plasminogen activator receptor-targeted nanoprobe in rhesus monkeys. Int J Nanomedicine (2015) 0.76
Functionalized milk-protein-coated magnetic nanoparticles for MRI-monitored targeted therapy of pancreatic cancer. Int J Nanomedicine (2016) 0.76
The nanomaterial toolkit for neuroengineering. Nano Converg (2016) 0.75
Magnetic nanoparticles for precision oncology: theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy. Nanomedicine (Lond) (2016) 0.75
Enhanced MRI T 2 Relaxivity in Contrast-Probed Anchor-Free PEGylated Iron Oxide Nanoparticles. Nanoscale Res Lett (2017) 0.75
Microwave-assisted green synthesis of superparamagnetic nanoparticles using fruit peel extracts: surface engineering, T 2 relaxometry, and photodynamic treatment potential. Int J Nanomedicine (2016) 0.75
Macrophage phagocytosis alters the MRI signal of ferumoxytol-labeled mesenchymal stromal cells in cartilage defects. Sci Rep (2016) 0.75
Enhanced magnetic resonance imaging and staining of cancer cells using ferrimagnetic H-ferritin nanoparticles with increasing core size. Int J Nanomedicine (2015) 0.75
Noninvasive monitoring of early antiangiogenic therapy response in human nasopharyngeal carcinoma xenograft model using MRI with RGD-conjugated ultrasmall superparamagnetic iron oxide nanoparticles. Int J Nanomedicine (2016) 0.75
Double-receptor-targeting multifunctional iron oxide nanoparticles drug delivery system for the treatment and imaging of prostate cancer. Int J Nanomedicine (2017) 0.75
Activatable interpolymer complex-superparamagnetic iron oxide nanoparticles as magnetic resonance contrast agents sensitive to oxidative stress. Colloids Surf B Biointerfaces (2017) 0.75
Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials (2005) 11.01
Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev (2008) 8.23
Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med (2006) 7.05
Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed (2004) 6.94
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol (2005) 5.60
Theory of NMR signal behavior in magnetically inhomogeneous tissues: the static dephasing regime. Magn Reson Med (1994) 4.60
Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol (2001) 4.54
In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation (2003) 4.00
Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology (2003) 3.71
Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging. J Am Chem Soc (2005) 3.67
FeCo/graphitic-shell nanocrystals as advanced magnetic-resonance-imaging and near-infrared agents. Nat Mater (2006) 3.34
Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev (2009) 3.17
Multifunctional magnetic nanoparticles: design, synthesis, and biomedical applications. Acc Chem Res (2009) 3.04
Nanomedicine. N Engl J Med (2010) 2.97
Nanoparticle-based theranostic agents. Adv Drug Deliv Rev (2010) 2.86
Multimodality imaging probes: design and challenges. Chem Rev (2010) 2.61
Chemical design of nanoparticle probes for high-performance magnetic resonance imaging. Angew Chem Int Ed Engl (2008) 2.59
Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev (2009) 2.57
Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn Reson Med (2005) 2.55
Synthesis, functionalization, and biomedical applications of multifunctional magnetic nanoparticles. Adv Mater (2010) 2.52
Positive contrast visualization of iron oxide-labeled stem cells using inversion-recovery with ON-resonant water suppression (IRON). Magn Reson Med (2007) 2.49
Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. Proc Natl Acad Sci U S A (1999) 2.42
Sizing it up: cellular MRI using micron-sized iron oxide particles. Magn Reson Med (2005) 2.38
Nanoscaling laws of magnetic nanoparticles and their applicabilities in biomedical sciences. Acc Chem Res (2008) 2.37
Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics (2012) 2.35
PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials (2010) 2.31
Development of a T1 contrast agent for magnetic resonance imaging using MnO nanoparticles. Angew Chem Int Ed Engl (2007) 2.19
In vivo magnetic resonance tracking of magnetically labeled cells after transplantation. J Cereb Blood Flow Metab (2002) 1.99
Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small (2009) 1.93
Clinical ultrashort echo time imaging of bone and other connective tissues. NMR Biomed (2006) 1.87
Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res (2009) 1.86
Preparation of magnetically labeled cells for cell tracking by magnetic resonance imaging. Methods Enzymol (2004) 1.82
EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res (2010) 1.79
Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation (2002) 1.77
T1 and T2 relaxivity of intracellular and extracellular USPIO at 1.5T and 3T clinical MR scanning. Eur Radiol (2005) 1.69
Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy. Acc Chem Res (2011) 1.69
Iron oxide nanoparticle platform for biomedical applications. Curr Med Chem (2009) 1.63
On T2-shortening by weakly magnetized particles: the chemical exchange model. Magn Reson Med (2001) 1.61
Magnetic nanoparticles for MR imaging: agents, techniques and cardiovascular applications. Basic Res Cardiol (2008) 1.60
Coating optimization of superparamagnetic iron oxide nanoparticles for high T2 relaxivity. Nano Lett (2010) 1.58
Critical enhancements of MRI contrast and hyperthermic effects by dopant-controlled magnetic nanoparticles. Angew Chem Int Ed Engl (2009) 1.57
Size and surface effects on the MRI relaxivity of manganese ferrite nanoparticle contrast agents. Nano Lett (2007) 1.56
Metallic iron nanoparticles for MRI contrast enhancement and local hyperthermia. Small (2008) 1.53
Theory of 1/T1 and 1/T2 NMRD profiles of solutions of magnetic nanoparticles. Magn Reson Med (1995) 1.51
SWIFT detection of SPIO-labeled stem cells grafted in the myocardium. Magn Reson Med (2010) 1.49
Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology (1988) 1.46
Noninvasive detection of macrophage-rich atherosclerotic plaque in hyperlipidemic rabbits using "positive contrast" magnetic resonance imaging. J Am Coll Cardiol (2008) 1.35
Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab (2009) 1.35
Off-resonance saturation as a means of generating contrast with superparamagnetic nanoparticles. Magn Reson Med (2006) 1.34
Hollow manganese oxide nanoparticles as multifunctional agents for magnetic resonance imaging and drug delivery. Angew Chem Int Ed Engl (2009) 1.34
In vivo off-resonance saturation magnetic resonance imaging of alphavbeta3-targeted superparamagnetic nanoparticles. Cancer Res (2009) 1.32
Generating positive contrast from off-resonant spins with steady-state free precession magnetic resonance imaging: theory and proof-of-principle experiments. Phys Med Biol (2006) 1.30
The effects of iron oxides on proton relaxivity. Magn Reson Imaging (1989) 1.29
Controlled clustering of superparamagnetic nanoparticles using block copolymers: design of new contrast agents for magnetic resonance imaging. J Am Chem Soc (2006) 1.21
Noninvasive monitoring of embryonic stem cells in vivo with MRI transgene reporter. Tissue Eng Part C Methods (2009) 1.19
Relaxometry and magnetometry of the MR contrast agent MION-46L. Magn Reson Med (1999) 1.15
HER2 targeted molecular MR imaging using a de novo designed protein contrast agent. PLoS One (2011) 1.09
Ultrashort T2* relaxometry for quantitation of highly concentrated superparamagnetic iron oxide (SPIO) nanoparticle labeled cells. Magn Reson Med (2009) 1.09
HSA coated MnO nanoparticles with prominent MRI contrast for tumor imaging. Chem Commun (Camb) (2010) 1.08
Self-refocused spatial-spectral pulse for positive contrast imaging of cells labeled with SPIO nanoparticles. Magn Reson Med (2009) 1.05
High throughput magnetic resonance imaging for evaluating targeted nanoparticle probes. Bioconjug Chem (2002) 1.05
In vivo cellular imaging of lymphocyte trafficking by MRI: a tumor model approach to cell-based anticancer therapy. Magn Reson Med (2006) 1.03
T₁-weighted ultrashort echo time method for positive contrast imaging of magnetic nanoparticles and cancer cells bound with the targeted nanoparticles. J Magn Reson Imaging (2011) 1.03
Optimization of iron oxide nanoparticle detection using ultrashort echo time pulse sequences: comparison of T1, T2*, and synergistic T1- T2* contrast mechanisms. Magn Reson Med (2011) 1.01
Magnetic iron oxide nanoparticles for biomedical applications. Future Med Chem (2010) 0.99
Superparamagnetic iron oxide particles and positive enhancement for myocardial perfusion studies assessed by subsecond T1-weighted MRI. Magn Reson Imaging (1993) 0.94
Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy. J Control Release (2010) 0.93
Comparison of superparamagnetic and ultrasmall superparamagnetic iron oxide cell labeling for tracking green fluorescent protein gene marker with negative and positive contrast magnetic resonance imaging. Mol Imaging (2009) 0.89
Positive contrast technique for the detection and quantification of superparamagnetic iron oxide nanoparticles in MRI. NMR Biomed (2010) 0.85
Quantification of SPIO nanoparticles in vivo using the finite perturber method. Magn Reson Med (2010) 0.83
Dual contrast enhancement of both T1- and T2-weighted sequences using ultrasmall superparamagnetic iron oxide. Magn Reson Imaging (1993) 0.82
Off-resonance saturation MRI of superparamagnetic nanoprobes: theoretical models and experimental validations. J Magn Reson (2011) 0.77
In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol (2007) 7.33
The iPlant Collaborative: Cyberinfrastructure for Plant Biology. Front Plant Sci (2011) 4.16
In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol (2005) 3.92
In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. Nat Nanotechnol (2009) 3.21
Epidemiologic features of severe fever with thrombocytopenia syndrome in China, 2011-2012. Clin Infect Dis (2013) 2.46
Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine (2008) 2.20
Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin (2008) 2.15
Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small (2009) 1.93
Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res (2009) 1.86
Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem (2006) 1.83
EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res (2010) 1.79
A wireless brain-machine interface for real-time speech synthesis. PLoS One (2009) 1.73
Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation. PLoS One (2010) 1.70
Protein energetic conformational analysis from NMR chemical shifts (PECAN) and its use in determining secondary structural elements. J Biomol NMR (2005) 1.62
Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr Drug Discov Technol (2009) 1.60
PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal (2007) 1.58
Probabilistic Identification of Spin Systems and their Assignments including Coil-Helix Inference as Output (PISTACHIO). J Biomol NMR (2005) 1.56
Structures of thymidine kinase 1 of human and mycoplasmic origin. Proc Natl Acad Sci U S A (2004) 1.56
Positive and negative emotional verbal stimuli elicit activity in the left amygdala. Neuroreport (2002) 1.55
Calf muscle perfusion at peak exercise in peripheral arterial disease: measurement by first-pass contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging (2007) 1.54
Metallic iron nanoparticles for MRI contrast enhancement and local hyperthermia. Small (2008) 1.53
Real-time detection of gene expression in cancer cells using molecular beacon imaging: new strategies for cancer research. Cancer Res (2005) 1.49
Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles. Gastroenterology (2009) 1.47
Adaptor protein complex-4 (AP-4) deficiency causes a novel autosomal recessive cerebral palsy syndrome with microcephaly and intellectual disability. J Med Genet (2010) 1.43
Using human extra-cortical local field potentials to control a switch. J Neural Eng (2004) 1.42
Motion-guided segmentation for cine DENSE MRI. Med Image Anal (2008) 1.40
Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res (2009) 1.39
Extracorporeal shock wave lithotripsy is effective in treating single melamine induced urolithiasis in infants and young children. J Urol (2012) 1.38
Neurotrophic electrode: method of assembly and implantation into human motor speech cortex. J Neurosci Methods (2008) 1.34
Quantum dots and multifunctional nanoparticles: new contrast agents for tumor imaging. Nanomedicine (Lond) (2006) 1.32
KLF5 Interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol Chem (2006) 1.30
Quantification of the heterogeneity in breast cancer cell lines using whole-cell impedance spectroscopy. Clin Cancer Res (2007) 1.29
Epidemiologic characteristics of cases for influenza A(H7N9) virus infections in China. Clin Infect Dis (2013) 1.28
Rational design of protein-based MRI contrast agents. J Am Chem Soc (2008) 1.28
Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano (2013) 1.28
Thymidine kinase 2 mutations in autosomal recessive progressive external ophthalmoplegia with multiple mitochondrial DNA deletions. Hum Mol Genet (2011) 1.26
Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgammaMPS copolymer coating. Biomaterials (2010) 1.25
The crystal structure of human adenylate kinase 6: An adenylate kinase localized to the cell nucleus. Proc Natl Acad Sci U S A (2005) 1.23
Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res (2006) 1.23
Noninvasive monitoring of embryonic stem cells in vivo with MRI transgene reporter. Tissue Eng Part C Methods (2009) 1.19
Toxic effects of iron oxide nanoparticles on human umbilical vein endothelial cells. Int J Nanomedicine (2010) 1.19
Superantigens and streptococcal toxic shock syndrome. Emerg Infect Dis (2003) 1.17
Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood. Biomaterials (2011) 1.14
Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol Pharmacol (2006) 1.14
Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET. Clin Cancer Res (2008) 1.13
A case of idiopathic azygos vein aneurysm and review of the literature. J Thorac Imaging (2012) 1.13
Blocking ion channel KCNN4 alleviates the symptoms of experimental autoimmune encephalomyelitis in mice. Eur J Immunol (2005) 1.10
Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer (2005) 1.10
HER2 targeted molecular MR imaging using a de novo designed protein contrast agent. PLoS One (2011) 1.09
Neural networks active during tactile form perception: common and differential activity during macrospatial and microspatial tasks. Int J Psychophysiol (2003) 1.09
3D myocardial tissue tracking with slice followed cine DENSE MRI. J Magn Reson Imaging (2008) 1.09
Current and future clinical applications for optical imaging of cancer: from intraoperative surgical guidance to cancer screening. Semin Oncol (2011) 1.07
Altered brain activation during cognitive control in patients with moderate to severe traumatic brain injury. Neurorehabil Neural Repair (2006) 1.06
Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and 1H-15N TROSY experiments. Chem Biol Drug Des (2009) 1.05
The interplay between SUCLA2, SUCLG2, and mitochondrial DNA depletion. Biochim Biophys Acta (2011) 1.05
Mapping right ventricular myocardial mechanics using 3D cine DENSE cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2012) 1.04
T₁-weighted ultrashort echo time method for positive contrast imaging of magnetic nanoparticles and cancer cells bound with the targeted nanoparticles. J Magn Reson Imaging (2011) 1.03
Immobilization of magnetic iron oxide nanoparticles on laponite discs - an easy way to biocompatible ferrofluids and ferrogels. J Mater Chem (2010) 1.02
Targeted transgenic overexpression of mitochondrial thymidine kinase (TK2) alters mitochondrial DNA (mtDNA) and mitochondrial polypeptide abundance: transgenic TK2, mtDNA, and antiretrovirals. Am J Pathol (2007) 1.02
Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells. Endocr Relat Cancer (2011) 1.01
The in vitro and in vivo protective activity of monoclonal antibodies directed against Hantaan virus: potential application for immunotherapy and passive immunization. Biochem Biophys Res Commun (2002) 1.01
c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS One (2010) 1.01
Displacement-encoded and manganese-enhanced cardiac MRI reveal that nNOS, not eNOS, plays a dominant role in modulating contraction and calcium influx in the mammalian heart. Am J Physiol Heart Circ Physiol (2011) 0.99
Comparison of brown and white adipose tissue fat fractions in ob, seipin, and Fsp27 gene knockout mice by chemical shift-selective imaging and (1)H-MR spectroscopy. Am J Physiol Endocrinol Metab (2012) 0.97
Structure of the substrate complex of thymidine kinase from Ureaplasma urealyticum and investigations of possible drug targets for the enzyme. FEBS J (2005) 0.96
Tactile discrimination of grating orientation: fMRI activation patterns. Hum Brain Mapp (2005) 0.95
Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells. Mol Cancer Ther (2011) 0.95
Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles. ACS Nano (2011) 0.95
Expression and preliminary functional analysis of Siglec-F on mouse macrophages. J Zhejiang Univ Sci B (2012) 0.94
Myocardial 3D strain calculation by combining cine displacement encoding with stimulated echoes (DENSE) and cine strain encoding (SENC) imaging. Magn Reson Med (2009) 0.93
Active targeting using HER-2-affibody-conjugated nanoparticles enabled sensitive and specific imaging of orthotopic HER-2 positive ovarian tumors. Small (2013) 0.93
Molecular characterization of thymidine kinase from Ureaplasma urealyticum: nucleoside analogues as potent inhibitors of mycoplasma growth. Mol Microbiol (2003) 0.93
Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy. J Control Release (2010) 0.93
Molecular photoacoustic tomography of breast cancer using receptor targeted magnetic iron oxide nanoparticles as contrast agents. J Biophotonics (2012) 0.92
Validation of in vivo 2D displacements from spiral cine DENSE at 3T. J Cardiovasc Magn Reson (2015) 0.92
Casein-coated iron oxide nanoparticles for high MRI contrast enhancement and efficient cell targeting. ACS Appl Mater Interfaces (2013) 0.91
Anti-HER2 antibody and ScFvEGFR-conjugated antifouling magnetic iron oxide nanoparticles for targeting and magnetic resonance imaging of breast cancer. Int J Nanomedicine (2013) 0.91
Effects of severity of traumatic brain injury and brain reserve on cognitive-control related brain activation. J Neurotrauma (2009) 0.91
Evaluation of the overall program effectiveness of HIV-related intervention programs in a community in Sichuan, China. Sex Transm Dis (2007) 0.91
Molecular mechanism of upregulation of survivin transcription by the AT-rich DNA-binding ligand, Hoechst33342: evidence for survivin involvement in drug resistance. Nucleic Acids Res (2007) 0.90
HRMAS 1H-NMR measured changes of the metabolite profile as mesenchymal stem cells differentiate to targeted fat cells in vitro: implications for non-invasive monitoring of stem cell differentiation in vivo. J Tissue Eng Regen Med (2008) 0.90